EBElina Berliba

Elina Berliba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elina Berliba has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hamartoamele biliare ca factori de confuzie în evaluarea non-invazivă a fibrozei hepatice

    by Eugen Tcaciuc, Elina Berliba, Mariana Ous-Cebotar, Catalina Olaru-Stavila, Nicoleta Costin, Felicia Secrieru

    Biliary hamartomas are benign hepatic malformations scattered throughout the parenchyma, which are usually asymptomatic. However, the diagnostic dilemmas they may cause justify the need for their thorough investigation. The aim of this article is to present the clinical case of a 55-year-old man with biliary hamartomas who was initially misdiagnosed with hepatic fibrosis based on elastography findings. For this purpose we used patient’s medical records, laboratory tests, imaging studies, and histopathological evaluations. The symptoms that led the patient to seek medical attention were very nonspecific: abdominal discomfort, bloating, and general fatigue. Paraclinical assessments remained inconclusive for a long time, suggesting progressive liver fibrosis. However, histopathological examination of hepatic tissue revealed no signs of fibrosis but confirmed the presence of biliary hamartomas, which were found to be the cause of the previous overestimation of fibrosis. Subsequently, contrast-enhanced magnetic resonance cholangiopancreatography was performed to assess the size (less than 4 mm) and hepatic distribution (segments VI and VIII) of the hamartomas. These findings allow us to conclude that biliary hamartomas are small hepatic lesions that rarely have a significant impact on the patient’s health, but their identification can be challenging due to the nonspecific clinical presentation and equivocal imaging features. Once diagnosed, careful monitoring is essential due to the potential risk of malignant transformation.

  • Open Access

    Vocea tăcută a ficatului într-o boală sistemică. studiu de caz în sarcoidoza hepatică

    by Eugen Tcaciuc, Elina Berliba, Catalina Olaru-Stavila, Mariana Ous-Cebotar, Ana Maria Badarau

    Sarcoidosis is a systemic inflammatory disease of unknown etiology that may, in atypical cases, involve the liver. Hepatic manifestations are often subtle, heterogeneous, and nonspecific, which can mislead clinicians and delay an accurate diagnosis. Liver biopsy with histological examination remains the gold standard for diagnosis, playing a critical role in confirming hepatic sarcoidosis. We report the case of a 43-year-old female patient admitted to the hepatology department with persistent right upper quadrant pain and fatigue. Biochemical analysis revealed a cytolytic and cholestatic pattern, while complete blood count showed anemia and thrombocytosis. Viral, tumor, and autoimmune liver markers were within reference ranges. Abdominal ultrasound and computed tomography (CT) revealed hepatomegaly. Hematologic malignancies were ruled out. The diagnosis of hepatic sarcoidosis was established by histopathological examination of a liver biopsy. Considering the frequent association with pulmonary sarcoidosis, a thoracic CT scan was performe which revealed mediastinal lymphadenopathy. The patient was subsequently referred to the pulmonology team, where immunosuppressive therapy was initiated, with favorable clinical and laboratory evolution. This case highlights an unusual presentation of hepatic involvement in systemic sarcoidosis. It underscores the importance of a multidisciplinary approach to achieve timely diagnosis and initiate appropriate pathogenetic treatment, particularly in the presence of unexplained hepatic abnormalities.

  • A case report of primary hepatic amyloidosis manifesting as severe cholestasis and acute liver failure

    by Eugen Tcaciuc, Elina Berliba, Calina Bugor, Ruslan Pretula, Catalina Olaru-Stavila, Ana Maria Badarau

    Introduction. Hepatic amyloidosis is characterized by the deposition of fibrillar amyloid proteins, which result from light chain amyloidosis (AL) immunoglobulin fragments, in the extracellular space and the vessel walls of the liver. A case of primary hepatic amyloidosis without evidence of a primary or secondary cause of amyloid deposition is rare. This case was unique to the Republic of Moldova, presenting a diagnostic and therapeutic challenge for clinicians. Because the liver is rarely affected, this pathology remains underdiagnosed and is associated with a reserved prognosis. Clinical case presentation. An unusual case of primary hepatic amyloidosis is reported in a previously asymptomatic 59-year-old woman who presented at admission with peripheral edema, ascites, and hepatomegaly. Biochemical tests revealed severe cholestasis with normal bilirubin levels and acute liver failure. Liver damage caused by viral hepatitis or autoimmune diseases was excluded. A percutaneous bone marrow biopsy was normal, and Bence Jones protein was negative, indicating no evidence of primary amyloidosis. The definitive diagnosis was based on liver biopsy, which revealed apple green birefringence on polarizing microscopy after positive Congo red staining. Conclusions. The reported case highlights the need to differentiate between infiltrative diseases, such as amyloidosis, when a patient presents with rapidly progressive severe cholestasis and acute liver failure. Future studies should focus on the availability of specific therapies for primary amyloidosis to improve the survival rate of these patients.

  • Open Access

    Hepatita autoimună în sarcină: prezentare de caz

    by Elina Berliba, Ina Vasilenco, Eugen Tcaciuc, Liudmila Tofan-Scutaru

    Autoimmune hepatitis (AIH) is a progressive chronic liver disease of unknown cause, with varied clinical picture and evolution. The diagnosis of autoimmune hepatitis is based on histological changes (interface hepatitis), characteristic clinical and biological signs (hypertransaminasemia and increased serum IgG concentration), with the presence of one or more characteristic autoantibodies. The purpose of this presentation was to analyze the evolution of the disease of a patient with autoimmune hepatitis during pregnancy, the safety of the treatment, and the long-term results/complications of immunosuppressive therapy. During this period, the patient periodically stopped the treatment, had a pregnancy that ended with the intrauterine death of the fetus, and then managed to give birth to a healthy child. Predniso(lo)n as initial therapy, followed by the addition of azathioprine after two weeks, are the first-line treatment for AIH, including in pregnancy. In our patient, immunosuppressive therapy with prednisone and azathioprine was safe and effective in inducing and maintaining remission, without significant complications or exacerbation during the pregnancy. Thus, an early established diagnosis and the prompt application of appropriate treatment, strict monitoring of the disease and of immunosuppressive treatment complications, can improve the evolution of AIH, slowing the progression of the disease.

  • Open Access

    A case of primary biliary cholangitis – diagnostic and treatment approaches

    by Ana Fita, Elina Berliba, Eugen Tcaciuc, Angela Peltec, Tatiana Burda

    Primary biliary cholangitis (PBC) is a chronic, autoimmune, slowly progressive liver disease, characterized by the presence of antimitochondrial antibodies (AMA), cholestatic syndrome, and histological lesions of the interlobular bile ducts, with the potential progression to liver fibrosis and cirrhosis. AMA or AMA-M2 are specific markers for diagnosis of PBC, detected in about 90 % of patients. Antinuclear antibodies (ANA) specific for primary biliary cholangitis, anti-sp100 or anti-gp210 subtypes, can be used as markers of PBC diagnosis in case of patients with negative AMA. In addition to being specific for diagnosis of PBC, the presence of anti-gp210 was associated with more severe forms, rapid progression and poor prognosis of the disease. The first therapeutic option for PBC is considered ursodeoxycholic acid (UDCA), and for patients with a suboptimal response, it is recommended second-line treatment with obeticholic acid. 8-10 % of patients with PBC may have overlap syndrome with autoimmune hepatitis (AIH), which occurs with biochemical, serological and/or histological features of AIH in patients with cholestatic manifestations of PBC. „Paris Criteria” help to identify patients with PBC/AIH overlap syndrome. The article also examines a clinical case of PBC, AMA negative, which required additional investigations for evaluation, diagnostic discussion and current management of overlap syndrome associating PBC and autoimmune hepatitis.